Purpose: EGF receptor (EGFR) is highly overexpressed on several cancers and two targeted
anti-EGFR antibodies which differ by isotype are FDA-approved for clinical use. Cetuximab …

Purpose: Tumor antigen–specific monoclonal antibodies (mAb) block oncogenic signaling
and induce Fcγ receptor (FcγR)–mediated cytotoxicity. However, the role of CD8+ CTL and …

The tumor antigen (TA)-targeted monoclonal antibodies (mAb) cetuximab and panitumumab
target the human epidermal growth factor receptor and have been integrated into treatment …

Objective To determine if the epidermal growth factor receptor (EGFR)-specific monoclonal
antibodies (mAbs) cetuximab or panitumumab mediate in vitro immune activation against …

The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor
involved in the proliferation and survival of cancer cells. EGFR is the first molecular target …

Immunotherapy with the EGFR-specific mAb cetuximab is clinically effective in 10–20% of
patients with squamous cell carcinoma of the head and neck (SCCHN). Little information is …

Head and neck squamous cell carcinomas (HNSCC) exhibiting resistance to the EGFR-
targeting drug cetuximab poses a challenge to their effective clinical management. Here, we …

Importance of the field: EGFR is an established therapeutic target in head and neck
squamous cell carcinoma (HNSCC). The EGFR-targeting monoclonal antibody cetuximab …

Background Myeloid-derived suppressor cells (MDSC) and M2 monocytes/macrophages
are two types of suppressive myeloid antigen presenting cells that have been shown to …

Head and neck cancers (HNC) represent the seventh most frequent cancer worldwide, with
squamous cell carcinomas as the most frequent histologic subtype. Standard treatment for …